SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

mF International Ltd. is a holding company, which engages in the development and provision of financial trading solutions through its subsidiary. It offers real-time mission critical forex, bullion and commodities trading platform solutions, financial value-added services, mobile applications, and financial information for brokers and institutional clients via internet or platform as software as a service. The company was founded by Tai Wai Lam and Chi Weng Tam on June 15, 2022, and is headquartered in Hong Kong.

mF International Ltd - Ordinary Shares - Class A

mF International Ltd

MFI is trending due to a significant price surge following the announcement of a $500M private placement to fund a digital asset treasury strategy, specifically Bitcoin Cash (BCH). The community is actively debating the company's strategic shift into crypto, the potential for dilution from the new share issuance, and whether this is a sustainable move or a classic pump-and-dump scheme, especially given MFI's history and the volatile nature of digital asset investments.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

CAPR is trending as investors eagerly await topline data from its Phase 3 HOPE-3 trial, with community chatter focused on potential outcomes and FDA approval scenarios. Discussions include the possibility of a short squeeze and speculation around the timing of the data release, expected in the coming weeks. Community members are weighing the potential for positive results in treating Duchenne Muscular Dystrophy and the impact on the company's future.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending as investors react to the company's AI strategy and substantial debt, with community discussions focusing on potential risks and opportunities. Concerns about rising credit-default swap costs and reliance on OpenAI are being weighed against Oracle's ongoing investments in AI infrastructure. Investor sentiment appears divided, with some seeing a buying opportunity amid the recent selloff, while others express skepticism about the company's long-term prospects.

Scilex Holding Co. engages in the acquisition, development, and commercialization of non-opioid pain management products for the treatment of acute and chronic pain. Its products include ZTLido, Elyxyb, and Gloperba. The company was founded on February 21, 2020 and is headquartered in Palo Alto, CA.

Scilex Holding Company

Scilex Holding Company ($SCLX) is trending amid discussions about its relationship with Datavault AI ($DVLT) and a proposed meme coin dividend for shareholders. The community is focused on the potential for a short squeeze, driven by the mechanics of the dividend distribution and related obligations for short sellers. Some investors express concerns about company management and financial strategy.

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), Global Services (BGS), and Boeing Capital (BCC). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The Boeing Capital segment seeks to ensure that Boeing customers have the financing they need to buy and take delivery of their Boeing product and manages overall financing exposure. The company was founded by William Edward Boeing on July 15, 1916 and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as investors weigh a potential bounce against persistent headwinds. Community members are closely watching for news on the union strike vote and its impact on production, while also considering the recent analyst downgrade and general market weakness. Despite positive order news, concerns linger about execution, profitability, and ongoing certification delays.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

Eli Lilly's stock is trending as it approaches a $1 trillion market cap, fueled by excitement around its diabetes and weight-loss drugs like Mounjaro and Zepbound. Community discussions revolve around the company's potential for further growth and possible stock splits, as well as its competition with other players in the GLP-1 market. Some traders are taking profits, while others anticipate continued upward momentum, drawing comparisons to tech giants and speculating about future catalysts.

SU Group Holdings Ltd. engages in the provision of security-related engineering services, and security guarding and screening services. It operates through the Security-Related Engineering Services and Security Guarding and Screening Services segments. The company was founded by Ming Chan in 1998 and is headquartered in Hong Kong.

SU Group Holdings Ltd. - Ordinary Shares - Class A

SU Group Holdings Ltd.

SUGP is trending as traders discuss its regained NASDAQ compliance, drawing parallels to other Hong Kong-based stocks that have recently experienced significant gains. A substantial contract is noted as a potential catalyst, while community members actively speculate on a potential short squeeze due to the stock's low float and high cost to borrow.

Enviri Corp. engages in the provision of industrial services and engineered products. It operates through the following segments: Harsco Environmental, Clean Earth, and Harsco Rail. The Harsco Environmental segment offers on-site services, under long-term contracts which may contain multiple performance obligations. The Clean Earth segment refers to specialty waste processing and beneficial reuse solutions for hazardous wastes, and soil and dredged materials. The Harsco Rail segment sells railway track maintenance equipment, after-market parts and safety and diagnostic equipment. The company was founded in 1853 and is headquartered in Philadelphia, PA.

Enviri Corp

Harsco Corp.

Shares of NVRI are trending after the company announced the sale of its Clean Earth business to Veolia for $3.04 billion and a spin-off of its other businesses into a new entity. The community is discussing the potential per-share value for shareholders following the deal, with some estimating significant upside. Some traders are watching for breakout levels and potential profit-taking opportunities.

Palatin Technologies, Inc. is a biopharmaceutical company, which engages in the development of medicines based on molecules that modulate the activity of the melanocortin receptor system. Its primary product candidate is marketed under the Vyleesi brand, the trade name for bremelanotide, which is used for the treatment of premenopausal women with acquired, generalized, hypoactive sexual desire disorder (HSDD). The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Princeton, NJ.

Palatin Technologies Inc.

Palatin Technologies ($PTN) is trending due to significant volatility and community discussion around a recent run-up and subsequent trading halts. Chatter revolves around whether the stock is a low-float rocket or a pump and dump, with some highlighting insider buying as a positive sign, while others point to dilution concerns and the company's history.

CCH Holdings Ltd. engages in operating a chicken restaurant. It offers catering services in Malaysia and outside Malaysia under the brand name, Chicken Claypot House for its chicken hotpot restaurants and Zi Wei Yuan for its fish head hotpot restaurants. The company was founded by Goh Kok Foong on December 2, 2024 and is headquartered in Seberang Perai, Malaysia.

CCH Holdings Ltd

CCHH is trending as traders discuss its recent climb since its October IPO, with some anticipating further gains. The community is debating potential price targets and speculating on whether the stock is being manipulated for a pump-and-dump scheme. Some traders are taking profits, while others suggest holding for a possible run to double digits.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of MAIA Biotechnology, Inc. (MAIA) soared 12% on Wednesday morning after the company said that it entered into a clinical master supply agreement with Swiss healthcare company Roche (RHHBY) for hard-to-treat cancer therapies.The <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.maiabiotech.com/news-events/press-releases/detail/141/maia-biotechnology-announces-master-clinical-supply">agreement</a> aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.Checkpoint inhibitors are a type of immunotherapy used to treat cancer. They work by blocking proteins called checkpoints that cancer cells use to evade the immune system.MAIA CEO Vlad Vitoc said that Ateganosine was found to be “highly synergistic and effective” in combination with Roche’s Atezolizumab in preclinical studies.MAIA’s Ateganosine is an investigational telomere-targeting agent currently in clinical development to evaluate its activity in non-small cell lung cancer (NSCLC). Telomeres, along with the enzyme telomerase, play a fundamental role in the survival of cancer cells and their resistance to current therapies.Ateganosine is presently being developed as a second or later line of treatment for NSCLC for patients who have progressed beyond the standard-of-care regimen of existing checkpoint inhibitors.On Stocktwits, retail sentiment around MAIA rose from ‘bearish’ to ‘bullish’ territory over the past 24 hours while message volume stayed unchanged at ‘low’ levels.<figure class="image"><img style="aspect-ratio:630/66;" src="https://news.stocktwits-cdn.com/Screenshot_2025_06_18_at_10_02_21_AM_png_d32286ea58.webp" alt="MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits" width="630" height="66"><figcaption>MAIA's Sentiment Meter and Message Volume as of 10:00 a.m. ET on June 18, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed optimism about the new agreement.<stembedurl>https://stocktwits.com/MoneyHelix/message/618266998</stembedurl>Another opined that it's “not bad news.”<stembedurl>https://stocktwits.com/share97/message/618262353</stembedurl><a href="https://stocktwits.com/symbol/MAIA">MAIA stock </a>is down by 11% this year and by over 47% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/air-india-boeing-crash-emergency-power-system-may-have-deployed-mid-flight/chls3JTRR2d">Air India Boeing Crash: Report Says Emergency Power System May Have Deployed Mid-Flight, Raising Engine Failure Concerns</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

MAIA’s New Agreement With Big Pharma Roche Turns Retail Investors Bullish As Stock Soars

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.

Equity

The agreement aims to support future studies investigating the combination of MAIA’s Ateganosine and Roche’s checkpoint inhibitor, Atezolizumab, for safe and effective cancer treatments.


This account has been verified as an official MAIA representative.

Verified Account

MAIA Biotechnology

MAIA Biotechnology, Inc. is a clinical stage biotechnology company that is engaged in the discovery, development and commercialization of therapies targeting cancer. Its product, THIO, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. The company was founded on August 3, 2018 and is headquartered in Chicago, IL.

MAIA
MAIA Biotechnology Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest MAIA News

MAIAMAIA Biotechnology Inc